Azetukalner

Bipolar Depression

Xenon Pharmaceuticals Inc.Phase 3Active

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 81/ 100

Competitive context

28 Active assets in the Bipolar Depression cohort.

Asset / Sponsor	Phase	Rating
Lurasidone NeuroRx, Inc.	Phase 4	A
LITHIUM, ELEMENTAL Dr. Inge Winter	Phase 4	BBB
Seroquel® Dr. Inge Winter	Phase 4	BBB
LAMOTRIGINE Stony Brook University	Phase 4	BBB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Joshua Rosenblat	Phase 4	BBB

View all 50 →

Same molecule, other indications

Azetukalner is also rated in:

focal epilepsyDormant

BB

Indicative ·

67 / 100

epilepsy with generalized tonic-clonic seizuresDormant

B

Indicative ·

60 / 100

bipolar I disorderDormant

B

Indicative ·

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.